ArticleJournal of travel medicine2026
Epidemiology and management of nitroimidazole-refractory giardiasis.
Article in Journal of travel medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nitroimidazole - albendazole combination therapy, quinacrine use, and risk factors in nitroimidazole-refractory giardiasis: a prospective multicentre observational study.BMC infectious diseases · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiardia is one of the most prevalent gastrointestinal protozoan pathogens globally. Nitroimidazole drugs are usually the first line of treatment, but nitroimidazole-refractory giardiasis (NRG), where infections fail to respond to these agents, is increasingly reported. At our centre, for laboratory-proven refractory giardiasis, a stepwise treatment ladder is used with albendazole plus tinidazole as second-line and mepacrine as third-line therapy.
methodsWe conducted a retrospective review between 2020 and 2024 at the Hospital for Tropical Diseases, London. Laboratory records identified adults and children with Giardia detected by stool microscopy or molecular methods. Treatment details and clinical information were extracted from electronic patient records. NRG and clearance failure were defined as a positive molecular test at least two weeks after completion of treatment.
resultsA total of 531 cases were identified. Of these, 59.0% (N = 311) were diagnosed through screening of high-risk individuals attending clinics for people seeking asylum and refugees (PSAR; Cohort A). The remaining 41.0% (N = 220) were symptomatic patients (Cohort B).In Cohort A, the prevalence of NRG was 36.3% (49/135), with children showing significantly higher odds of clearance failure compared to adults (adjusted OR, 4.81; 95% CI, 1.09-21.40; P = 0.0367). In Cohort B, 34.1% of treatment-naïve travellers had NRG. Travel to India was strongly associated with NRG (adjusted OR, 4.19; 95% CI, 1.72-11.00; P = 0.002). Second-line treatment regimens with albendazole plus tinidazole were effective, and third-line mepacrine therapy was well tolerated with no adverse reactions and successful in nearly all cases.
conclusionsNRG was common in both asymptomatic and symptomatic individuals, particularly among children seeking asylum and travellers who had visited India. NRG likely results from multiple factors, including protozoal drug resistance and host-related factors. While our current treatment ladder appears effective, further research is needed to understand the mechanisms underlying treatment failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.